SCHEMBL18647206

SCHEMBL18647206

Nc1ncnc2c1c(-c1ccc(Oc3ccc(F)cc3F)cc1)nn2[C@H]1C[C@@H](N)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 9/20 0.55
LCK P06239 2/20 0.55
LYN P07948 1/20 0.55
NUDT14 O95848 1/20 0.52
NUDT5 Q9UKK9 1/20 0.52
EGFR P00533 11/20 0.51
SRC P12931 10/20 0.50
KDR P35968 10/20 0.50
PIK3CD O00329 10/20 0.50
ABL1 P00519 9/20 0.50
HCK P08631 9/20 0.50
PIK3CA P42336 9/20 0.50
PIK3CB P42338 9/20 0.50
MTOR P42345 9/20 0.50
PIK3CG P48736 9/20 0.50
PRKDC P78527 9/20 0.50
EPHB4 P54760 8/20 0.50
PI4KB Q9UBF8 7/20 0.50
FYN P06241 1/20 0.49
TEK Q02763 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22902504 0.86 BTK (0.63) BTKLCKLYNNUDT14NUDT5
SCHEMBL18646643 0.85 EGFR (0.52) BTKLCKLYNNUDT14NUDT5
SCHEMBL18646642 0.84 BTK (0.65) BTKLCKLYNEGFRSRC
SCHEMBL18647205 0.83 RET (0.50) BTKLCKLYNEGFRSRC
SCHEMBL18645940 0.82 BTK (0.78) BTKLCKLYNNUDT14NUDT5
SCHEMBL19635808 0.82 BTK (0.67) BTKEGFRSRC
SCHEMBL19635807 0.82 BTK (0.67) BTKEGFRSRC
SCHEMBL19635218 0.81 BTK (0.68) BTKLCKLYNNUDT14NUDT5
SCHEMBL19635191 0.81 BTK (0.54) BTKLCKLYNNUDT14NUDT5
SCHEMBL19635788 0.81 BTK (0.68) BTKLCKLYNNUDT14NUDT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200247808-A1 Heterocyclic Tec-Family Kinase Inhibitors GB005, INC. 2020-08-06 US disclosed
WO-2017041180-A1 HETEROCYCLIC TEC-FAMILY KINASE INHIBITORS PHARMASCIENCE INC. (CA) 2017-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247808-A1 Heterocyclic Tec-Family Kinase Inhibitors TEC, BTK, LCK BTK 2/4885LCK 3/4885LYN 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.